Impact of hepatitis C virus and direct acting antivirals on kidney recipients

a retrospective study

Mohamed Gendia, Pietro Lampertico, Carlo Maria Alfieri, Roberta D'Ambrosio, Maria Teresa Gandolfo, Maria Rosaria Campise, Fabrizio Fabrizi, Piergiorgio Messa

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.

Original languageEnglish
Pages (from-to)493-501
Number of pages9
JournalTransplant International
Volume32
Issue number5
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Hepacivirus
Antiviral Agents
Retrospective Studies
Kidney
RNA
Proteinuria
Transplants
Hepatitis C Antibodies
Virus Diseases
Group Psychotherapy
Kidney Transplantation
Allografts
Safety
Liver
Enzymes
Therapeutics

Keywords

  • direct acting antivirals
  • graft outcome
  • hepatitis-C
  • kidney transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Impact of hepatitis C virus and direct acting antivirals on kidney recipients : a retrospective study. / Gendia, Mohamed; Lampertico, Pietro; Alfieri, Carlo Maria; D'Ambrosio, Roberta; Gandolfo, Maria Teresa; Campise, Maria Rosaria; Fabrizi, Fabrizio; Messa, Piergiorgio.

In: Transplant International, Vol. 32, No. 5, 01.05.2019, p. 493-501.

Research output: Contribution to journalArticle

@article{61b2cda4c4a44ec291a8e3776f749eb9,
title = "Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study",
abstract = "Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5{\%}) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30{\%}) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.",
keywords = "direct acting antivirals, graft outcome, hepatitis-C, kidney transplantation",
author = "Mohamed Gendia and Pietro Lampertico and Alfieri, {Carlo Maria} and Roberta D'Ambrosio and Gandolfo, {Maria Teresa} and Campise, {Maria Rosaria} and Fabrizio Fabrizi and Piergiorgio Messa",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/tri.13393",
language = "English",
volume = "32",
pages = "493--501",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Impact of hepatitis C virus and direct acting antivirals on kidney recipients

T2 - a retrospective study

AU - Gendia, Mohamed

AU - Lampertico, Pietro

AU - Alfieri, Carlo Maria

AU - D'Ambrosio, Roberta

AU - Gandolfo, Maria Teresa

AU - Campise, Maria Rosaria

AU - Fabrizi, Fabrizio

AU - Messa, Piergiorgio

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.

AB - Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.

KW - direct acting antivirals

KW - graft outcome

KW - hepatitis-C

KW - kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=85064839908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064839908&partnerID=8YFLogxK

U2 - 10.1111/tri.13393

DO - 10.1111/tri.13393

M3 - Article

VL - 32

SP - 493

EP - 501

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 5

ER -